Replies to post #127573 on Biotech Values

[DewDiligence]

Xarelto update: JNJ said on the 3Q11 CC that it intends to submit an sNDA for the ACS indication by the end of 2011.

[genisi]

Pending presentation of the full dataset from this study

It's out:

Bayer’s Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study

http://www.press.bayer.com/baynews/baynews.nsf/ID/1BB516127D005F31C125794700400491